Method Profile
Compare pharmacological heterogeneity among metastases from one patient against variation across patients.
Study the consequences of metastatic sampling and tumor phenotype for functional drug profiling.
213 organoids from colorectal liver metastases in 102 patients; multiple spatial lesions were represented for 65 patients.
96-hour ATP-associated viability screens in two drug libraries, with matched molecular and histological characterization.
Models
Microsatellite-stable colorectal liver-metastasis organoids from a surgically treated cohort.
Drug libraries
41- and 47-drug libraries with 24 shared drugs for principal cross-library comparisons.
Context
Morphology, mutations, gene expression and available radiological treatment histories.
Harmonize common drug ranges, compare model pairs at their stated sampling time and preserve the separation of lesion and patient denominators.
Biobank-scale multi-lesion pharmacology and two selected treatment examples.
213 models from 102 patients; two prospective treatment decisions were described.
Metastases within one patient versus models from different patients; cystic versus solid phenotypes.
Within-patient variation was lower overall but substantial in some patients; chemotherapy rechallenge and targeted therapy had different clinical outcomes.
A collection of 213 organoids from 102 patients compared liver metastases, molecular features and drug response. In two selected clinical cases, chemotherapy rechallenge produced a response, while metastases progressed during the targeted treatment.
